A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Executive Director - Clinical Research, Neurodegeneration

Biology & BiotechUpdated on Nov 13
Full-time$348.5k - $471.5k

About the Job

Requirements

  • An MD with a strong research background, or an MD/PhD, and a track record of successful research support and peer-reviewed publications.
  • Ten or more years of industry experience or equivalent clinical academic experience.
  • Sound scientific and clinical judgment.
  • A successful track record leading Phase 2/3 clinical programs, preferably in Huntington’s disease drug development, including major interactions with health authorities.
  • Familiarity with clinical research and clinical trial design concepts, including biostatistics, regulatory agency organization, guidelines, and practices.
  • Ability to effectively present ideas and document complex medical and clinical concepts in writing and orally.
  • A history of solving problems while exhibiting sound judgment and a balanced, realistic understanding of issues.
  • Leadership and collaboration skills in a matrix environment.

Responsibilities

  • Provide strategic leadership and a clear voice for clinical programs.
  • Develop realistic drug-development approaches and lead clinical efforts to secure global regulatory approvals.
  • Oversee trial conduct and safety.
  • Provide strategic consultation and guidance to Research on decisions with significant clinical components and implications.
  • Collaborate with Preclinical, Regulatory Affairs, Medical Affairs, and Commercial to integrate product development plans.
  • Ensure accountability through Clinical Research and Operations for relevant timelines and deliverables.
  • Lead and supervise major written deliverables, including regulatory submissions, original articles, and abstracts, as well as presentation materials.
  • Review and sign off, as appropriate under standard operating procedures, on controlled documents including protocols, investigator brochures, and informed consent forms.
  • Influence internal and external audiences, including at regulatory and scientific meetings.
  • Act as clinical lead physician for the Huntington’s program and support clinical development across therapeutic areas and stages as pipeline assets evolve.
  • Advise Research on the clinical development feasibility of novel targets and the design of proof-of-concept studies.
  • Collaborate extensively with external experts.
  • Lead early-phase clinical development programs from bench to bedside as opportunities arise.
  • Work in a matrix organization across Regulatory, Biostatistics, Clinical Operations, Preclinical, Commercial, and Quality Assurance teams to develop integrated strategies.
  • Serve as an Alnylam Development spokesperson at external meetings, including regulatory interactions and scientific meetings.

Desired Qualifications

  • Board certification or equivalent, or specialist training.
  • Drug-development experience in neurology, particularly Huntington’s disease.
  • Experience and knowledge working with biotech or pharmaceutical partners.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs